Evidence map›Paper›PMID 17602948›Full record

ReviewFree radical biology & medicine2007

Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy.

J David Lambeth

Open access · greenAbstract readReview
In one paragraph

Review in Free radical biology & medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 295 papers.

0numbers the graph read from it
0cells of the map it votes in
295citing papers in PubMed
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

295 citing papers in PubMed, 671 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

235 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

J David Lambeth148 Whitehead Biomedical Research Building, Department of Pathology and Laboratory Medicine, 615 Michael Street, Atlanta, GA 30322, USA. noxdoc@mac.com

Funding

Moxl as a Molecular Target for Cancer Drug DiscoveryR01CA084138 · NCI · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2000 to 2011
$4.4M
Regulation of Nox Enzymes by Calcium and Novel SubunitsR01CA105116 · NCI · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2004 to 2014
$2.4M
Dual Oxidases (Duox): Enzymology &Biological FunctionR01GM067717 · NIGMS · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2003 to 2006
$1.1M
Regulation of Nox Enzymes by Calcium and Novel SubunitsR56CA105116 · NCI · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2009 to 2009
$248k
NCI NIH HHS CA084138NCI NIH HHS CA105116NCI NIH HHS R01 CA084138NCI NIH HHS R01 CA105116NCI NIH HHS R56 CA105116NIGMS NIH HHS R01 GM067717
6 · The paper itself

Abstract

Reactive oxygen species (ROS) are considered to be chemically reactive with and damaging to biomolecules including DNA, protein, and lipid, and excessive exposure to ROS induces oxidative stress and causes genetic mutations. However, the recently described family of Nox and Duox enzymes generates ROS in a variety of tissues as part of normal physiological functions, which include innate immunity, signal transduction, and biochemical reactions, e.g., to produce thyroid hormone. Nature's "choice" of ROS to carry out these biological functions seems odd indeed, given its predisposition to cause molecular damage. This review describes normal biological roles of Nox enzymes as well as pathological conditions that are associated with ROS production by Nox enzymes. By far the most common conditions associated with Nox-derived ROS are chronic diseases that tend to appear late in life, including atherosclerosis, hypertension, diabetic nephropathy, lung fibrosis, cancer, Alzheimer's disease, and others. In almost all cases, with the exception of a few rare inherited conditions (e.g., related to innate immunity, gravity perception, and hypothyroidism), diseases are associated with overproduction of ROS by Nox enzymes; this results in oxidative stress that damages tissues over time. I propose that these pathological roles of Nox enzymes can be understood in terms of antagonistic pleiotropy: genes that confer a reproductive advantage early in life can have harmful effects late in life. Such genes are retained during evolution despite their harmful effects, because the force of natural selection declines with advanced age. This review discusses some of the proposed physiologic roles of Nox enzymes, and emphasizes the role of Nox enzymes in disease and the likely beneficial effects of drugs that target Nox enzymes, particularly in chronic diseases associated with an aging population.

Indexed as

Chronic DiseaseAlzheimer DiseaseAnimalsBone ResorptionBrainCardiovascular Physiological PhenomenaDiabetic AngiopathiesEar, InnerEndocrine SystemHumansHypertensionImmunity, InnateKidney DiseasesLungNADPH OxidasesNeoplasmsNADPH OxidasesReactive Oxygen Species

Identifiers

PMID17602948
PMCPMC2013737
OpenAlexW2122002245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.